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Abstract The hunt for pathogenic mitochondrial 
DNA (mtDNA) mutations is often fueled by the 
seeming novelty of mutations that are either nonsyn- 
onymous or affect the protein synthesis machinery in 
patients. In order to determine the novelty of a de­
tected mutation, the working geneticist nearly always 
consults MITOMAP - often exclusively. By reanalyz­
ing some case studies of refractory anemia with ring 
sideroblasts, prostate cancer, and hearing impairment, 
we demonstrate that the practice of solely relying on 
MITOMAP can be most misleading. A notorious 
example is the T1243C mutation, which was assessed to 
be novel and deemed to be associated with some (rare) 
disease simply because researchers did not realize that 
T1243C defines a deep branch in the Eurasian mtDNA 
phylogeny. The majority of ‘novel' mutations sus-
H.-J. Bandelt (13)
Department of Mathematics,
University of Hamburg, Bundesstr. 55,
20146 Hamburg, Germany
e-mail: bandelt@math.uni-hamburg.de
A. Salas
Unidad de Genética,
Instituto de Medicina Legal,
Facultad de Medicina,
Universidad de Santiago de Compostela, 
15782 Galicia, Spain
A. Salas
Centro Nacional de Genotipado (CeGen),
Hospital Clínico Universitario,
15706 Galicia, Spain
C. M. Bravi
Laboratorio de Genética Molecular Poblacional,
Instituto Multidisciplinario de Biología Celular (IMBICE), 
P.O. Box 403, 1900 La Plata, Argentina 
pected of being pathogenic are in actual fact known 
(and presumably neutral) polymorphisms (although 
unknown to MITOMAP). and this becomes glaringly 
evident when proper database searches and straight­
forward Internet queries are carried out.
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Introduction
What is a novel mitochondrial DNA (mtDNA) muta­
tion? At first sight the answer to this question appears 
to be utmost trivial: an observed mtDNA mutation or 
polymorphism is novel if it has not been observed be­
fore: that is. it has not been reported in the literature 
before or cannot be found in other publicly available 
sources. This, however, is not the manner in which the 
novelty of mtDNA mutations is perceived and treated 
in practice by the working human geneticist. Novelty is 
operationally defined by exactly two mouse clicks: with 
the first one the geneticist accesses http://www.mito- 
map.org/cgi-bin/mitomap/search.pl (click): with the 
second one he/she enters the targeted position number 
in the slot of “Search for:" (click): “please scroll 
down". And there, on the screen, is the answer. The 
results of applying this search method means that if 
you find the observed mtDNA mutation cited, you can 
copy-and-paste the citation into your paper: it is not 
novel. Conversely, with the answer “sorry, your query 
did not match any items in MITOMAP database for 
the selected category", you designate the new mutation 
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as “novel". If. in addition, this mutation, which either 
affects a ribosomal or transfer RNA gene or is coding 
and nonsynonymous, is not observed in some small 
convenience sample declared as “controls", then a case 
can be made for disease-association or pathogenicity. 
The seeming pathogenic role is then often ‘garnished' 
with the inferred consequences of the tertiary structure 
of the gene-product affected by that mutation.
Although this practice is not really supported by the 
more sophisticated strategies of weighing evidence for 
or against pathogenic status (Mitchell et al. 2006), it is 
nevertheless the standardly accepted protocol in al­
most all medical investigations. It is probably not well 
known nor greatly appreciated that MITOMAP is a 
database of rather limited scope and. consequently, 
quite problematic for two reasons: (1) it actually 
exhibits and classifies only a non-representative subset 
of the published mtDNA mutations, and (2) the 
mutations listed and sorted into different slots are 
mined from the articles without critical editing: that is. 
obviously flawed results would also find their way into 
the database (for a pertinent case, see Brandstatter 
et al. 2005). The user who innocently takes MITOMAP 
as the gold standard in the field can thus be seduced 
into making inadvertent interpretations of his/her 
mtDNA findings.
Methods
In a typical disease study a sequencing of the entire 
mitochondrial genome would reveal 5-50 mutations in 
the coding region relative to the revised Cambridge 
reference sequence (rCRS). These are then compared 
with public databases, such as the mtDNA database 
MITOMAP (Brandon et al. 2005: http://www.mito- 
map.org/). In addition to this database, as edited 27 
February 2006, there is the Uppsala mtDB database 
(Ingman and Gyllensten 2006: http://www.gen- 
pat.uu.se/mtDB/) maintained by Max Ingman. as edi­
ted 14 December 2005. This latter database hosts a 
large subset of complete mtDNA sequences or entire 
coding-region sequences that result from systematic 
sequencing efforts published mainly in the field of 
population genetics, with reference to the originally 
published sequences stored in GenBank.
For supplementary control-region information, one 
may use the SWGDAM database (http://www.fbi.gov/ 
hq/lab/fsc/backissu/april2002/millerl.htm). This foren­
sic mtDNA database lists more than 4800 partial con­
trol-region sequences (covering the two hypervariable 
segments): for some caveats, however, see Bandelt 
et al. (2004a, b). For some early references concerning 
control-region sequences, the Mitochondrial DNA 
Concordance database (Miller et al. 1996: http:// 
www.bioanth.cam.ac.uk/mtDNA/index.html) is quite 
useful. Note that this database was last updated 30 
April 1998, and no new sequences are currently being 
added to it. Sequence data recorded in the vast liter­
ature available on the mtDNA genome (mainly in 
forensic and human population genetic journals) have 
been used as well: this information includes approxi­
mately 40,000 profiles for the first hypervariable region 
(HVS-I) and approximately 15,000 profiles for the 
second hypervariable segment (HVS-II).
Views of the basal parts of the mtDNA phylogeny 
can be found in Herrnstadt et al. (2002), and updated 
haplogroup nomenclature and trees are given in pub­
lications by Kong et al. (2003, 2006) for East Asian 
mtDNA, by Palanichamy et al. (2004) for West Eur­
asian mtDNA, and by Kivisild et al. (2006) and Torroni 
et al. (2006) for African mtDNA. Estimates of mtDNA 
trees can also be downloaded from the mtDNA web­
page of Ian Logan (http://www.ilbgl8230.pwp.blue- 
yonder.co.uk/mtdna.htm), who has currently (as of 11 
May 2006) examined nearly 2500 complete mtDNA 
sequences - haplogroup by haplogroup - using the up- 
to-date haplogroup nomenclature. One should bear the 
caveat in mind that any tree estimate whatsoever may 
bear some typos or oversights and. even when correctly 
represented, necessarily hinges upon the current 
knowledge of the mtDNA pool and an understanding 
of the mutational process. As such, tree estimates may 
slightly change when more information becomes 
available.
Complete mtDNA sequences obtained in medical 
studies are scattered over the literature, and there are 
only a few sources available that put some of them into 
context (see Macaulay et al. 1999: Kivisild et al. 2002). 
In order to retrieve the primary sources, it is helpful to 
use general-purpose search engines provided in the 
Internet. We have taken Google and Google Scholar 
by way of example. Note that different country-specific 
Google versions may return slightly different search 
results.
Results
About refractory anemia with ring sideroblasts 
and the ‘novelty' of T9137C
Let us take an example from a recent study 
(Babusiakova et al. 2004), which highlights a number 
of ‘novel' mtDNA mutations, such as the transition at 
9137 relative to rCRS. MITOMAP does not offer any 
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information about this site. The user adhering strictly 
to MITOMAP would therefore infer that this mutation 
is new - that is. it has never been observed before. 
Now. entering the query “human mtDNA 9137" into a 
search engine, such as Google (Deutschland), returns 
more than 100 results. The first entry is the reference to 
a publication by Maca-Meyer et al. (2001), where the 
9137 transition was indeed recorded in a haplogroup 
HV lineage. The other hits are “cold", typically 
referring to page or telephone numbers. The same 
query in Google Scholar delivers yet another hit. one 
of Kong et al. (2004), where this mutation occurs in a 
table, with reference to the haplogroup F2a lineage 
from Kong et al. (2003). Both of these two complete 
mtDNA sequences from haplogroups HV and F2a, 
respectively, can also be retrieved from the mtDB 
database after entering the query for “9137 C".
When we enter “human mtDNA T9137C" into 
Google, we obtain the single reference to Máximo 
et al. (2002), which lists T9137C as a “somatic" 
mutation. The same query in Google Scholar delivers a 
second hit. namely De Joanna et al. (2000), who wrote 
that they "... found a new, homoplasmic T9137C 
mutation in the patient, but not in 50 control subjects: 
the mutation converts a moderately conserved isoleucine 
by tryptophan but its pathogenic role is unclear". In­
deed. the role of T9137C is still unclear, mainly be­
cause this mutation is rediscovered again and again in 
different contexts without any systematic analysis and 
screening of its natural occurrences in the mtDNA 
phylogeny.
Internet search for G6261A
To give another example, consider the transition at 
6261, which is also mentioned by Babusiaková et al. 
(2004). MITOMAP lists this mutation by referring only 
to the paper of Petros et al. (2005), which may evoke 
the impression that this mutation has something to do 
with prostate cancer. In reality, this mutation occurs in 
many parts of the mtDNA phylogeny and had already 
been observed prior to 2005 in the coding-region data 
of Herrnstadt et al. (2002, 2003) and in the complete 
mtDNA data of Tanaka et al. (2004) - altogether in at 
least six different haplogroups C. DI. D4e, H3. L3e3, 
and T2). More recently. Kivisild et al. (2006) also ob­
served this mutation in the Indian haplogroup M4b 
(sample no. AS10) and in a haplogroup T2 sequence 
(sample no. EU79). These references are all provided 
by the mtDB database. Entering “mtDNA 6261" into 
Google Scholar yields the reference to Howell et al. 
(2003) as the first entry, and we are thus led to the 
complete mtDNA sequence of their VIC 14 LHON 
pedigree. This mtDNA lineage belongs to haplogroup 
H3 and is closely related to coding-region sequence no. 
426 of Herrnstadt et al. (2002, 2003). The same query 
entered into Google gives the additional reference to 
Appendix SI of Loogvâli et al. (2004), where this ha­
plogroup H3 lineage no. 426 is displayed in the ha­
plogroup H mtDNA phylogeny. Moreover, with 
Google we find an early reference to Fliss et al. (2000), 
where this mutation was also listed.
As in the case of T9137C. we find another set of 
references when we initiate a Google search with 
“mtDNA G6261A" instead of “mtDNA 6261". Such a 
search has a high success rate because no page or 
telephone numbers or range numbers are detected and 
listed; on the other hand, such a search is bound to miss 
a number of relevant references that do not adhere to 
the usual notation of mtDNA mutations in medical 
genetics. The five hits offered by this new query are all 
relevant without exception: the first points to Petros 
et al. (2005) and the fourth and fifth to the same con­
text of prostate cancer with reference to the survey 
article by Wallace (2005).
The second item of the previous search result leads 
us to a haplogroup L3e tree, which is embedded in the 
mtDNA webpage of Ian Logan. His haplotype lists and 
trees can be most useful for the working human 
geneticist, and one may wonder why such necessary 
bookkeeping work is done by an amateur genealogist 
rather than by medical laboratories that regularly 
publish findings about ‘pathogenic' mtDNA mutations.
The third item from the Google results for “mtDNA 
G6261A" concerns a conference contribution (Arbuz­
ova et al. 2001), where the mutations G6261A together 
with C5187T, C7873T, C10822T, A10972G, and 
A14977G were found in a Down syndrome patient. 
This listing includes only those mutations that were 
determined not to have been described prior to the 
time of the conference contribution. Interestingly, 
there is a large overlap with the five private transitions 
at 5187, 6261, 7873,10822, and 11914 in the haplogroup 
T2 lineage no. 430 of Herrnstadt et al. (2002, 2003). 
Since G11914A is a mutation that has been known 
about for a long time (e.g. Tanaka and Ozawa 1994), 
we may well assume that this mutation was also present 
in that Down syndrome patient. Recently, Kivisild 
et al. (2006) have reported a haplogroup T2 lineage 
with private transitions at 783, 6261, 9524, 10822, 
11914,12346, and 15479. The Internet user is led to this 
and a subsequent reference through the initial Google 
search “mtDNA 6261". Fraumene et al. (2005) have 
analyzed 66 complete mtDNA sequences from a Sar­
dinian village (Ogliastra). Three of these belong to a 
particular branch of haplogroup T2 bearing transitions 
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at sites 146, 279, 5187, 6261, 7679, 7873, 10822, 15784, 
and 16292 [see Fraumene et al. (2006) for the sub­
sequent full publication]. Interestingly, the transition at 
279 within haplogroup T2 seems to be confined to this 
branch, as indicated by the presence of 146 and/or 
16292, which could be inferred from searching the 
SWGDAM mtDNA database. The sequence motif 
with transitions at 16126,16292, and 16294 in the HVS- 
I segment appears to be quite frequent in other parts of 
Sardinia as well (e.g. Fraumene et al. 2003). It would 
appear that this is a new basal branch of haplogroup T2 
that is partially characterized by G6261A and 
C16292T. Should we then, following Petros et al. 
(2005), expect an elevated frequency of prostrate 
cancer in Sardinia? It would be worth finding out 
whether carriers of this particular T2 subhaplogroup 
indeed bear a much higher cancer risk than non-car- 
riers.
Revisiting the ‘prostate cancer' mutation A6663G
In contrast to the highly recurrent G6261A, another 
mutation, A6663G (highlighted as novel by Babusia­
kova et al. 2004), which is also suspected to be con­
nected with prostate cancer (Petros et al. 2005; Wallace 
2005), seems to be an extremely rare event. In MI- 
TOMAP, the mutation A6663G appears in three cat­
egories - under “Coding Region Sequence 
Polymorphisms" (with reference to Scaglia et al. 2003), 
“Reported Mitochondrial DNA Base Substitution 
Diseases: Coding and Control Region Point Muta­
tions" (referring to Petros et al. 2005), and “Unpub­
lished MtDNA Polymorphisms" (Polyak and 
Vogelstein 1999).
Performing the same Internet search strategy as 
above, we come across ten occurrences of this mutation 
(Parfait et al. 1997; Polyak et al. 1998; Torroni et al. 
2001; Herrnstadt et al. 2002, 2003; Howell et al. 2004; 
Kivisild et al. 2006), all pointing to the same particular 
subhaplogroup of haplogroup L2al (sensu Kivisild 
et al. 2006). Note that the mutation screening of Parfait 
et al. (1997) was fairly incomplete at the time: at the 
very least the five COX transitions at 7175, 7274, 7771 
and 8206, 9221, which are characteristic for haplo- 
groups L2a and L2, should have been listed for the L2a 
lineages of their Patients 5 and 15. This sub-haplo- 
group is characterized by G3010A and A6663G in the 
coding region and possibly by further transitions at 
16193,16213,16239, and 513 in the control region. The 
corresponding samples are from Burkina Faso and 
from North or Central America. This specific mutation 
motif in HVS-I has also been found elsewhere: for 
example, in two mtDNAs from Guinea-Bissau (Rosa 
et al. 2004). One could certainly expect some popula­
tion substructure in regard to this minor subhaplo­
group. However, Petros et al. (2005) and Wallace 
(2005) failed to appreciate these particular circum­
stances. Before interpreting the (rare) presence of 
A6663G in patients with prostate cancer, it would have 
been necessary to carry out large-scale screening of 
males bearing this particular haplogroup L2a mtDNA 
type.
Misscored mutations
After going through the mutations declared to be 
‘novel' by Babusiakova et al. (2004) - one by one - we 
eventually find that all but one have already been re­
ported elsewhere (Maca-Meyer et al. 2001: Herrnstadt 
et al. 2002, 2003: Achilli et al. 2004: Coble et al. 2004). 
It therefore seems highly unlikely that this single, truly 
novel substitution, G15084T (in heteroplasmic state), 
detected by Babusiakova et al. (2004) can sustain their 
claim of an “accumulation of homoplasmic mtDNA 
point mutations'' in patients of refractory anemia with 
ring sideroblasts. Mutations at 1838, 11250, and 11457 
would also be novel mutations according to MITO- 
MAP. However, the polymorphisms “G1838A", 
“A11250G", and “A11457G" reported by Babusia­
kova et al. (2004) bear incorrect rCRS nucleotides. 
Therefore, one can safely regard these mutations as 
well as “G16154A" as typos (see our Table 1). On the 
other hand, the documented mtDNA variation is 
obviously incomplete, with one to seven mutations 
a Haplogroup allocation 
according to Palanichamy 
et al. (2004) and Achilli et al. 
(2004, 2005)
Table 1 Mutations missed or 
misreported in the study of 
Babusiakova et al. (2004)
Sample Haplogroup3 Missed mutations Misreported mutations
Patient A J2a C150T, T152T, A1438G, 
T4216C, A8860G, 
G11377A, C14766T
G16145A (as G16154A)
Patient B T2 A4917G A11251G (-1 shifted),
G1888A (as G1838A)
Patient C HV1 A2706G, C16067T
Control U5al T3197C, A16399G A11467G (-10 shifted),
C16256T (as G16256T)
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missing (Table 1); as such, it is not clear whether some 
mutation of potential disease status may have been 
overlooked.
Mutations that seem to be novel can also be gen­
erated by inadvertent scoring or through clerical er­
rors. For instance, the deletion 248del was declared to 
be an “unknown" mutation by Carew et al. (2003). 
Deletion of one A at positions 248-249, however, is 
normally scored as 249del, following the forensic con­
vention for nomenclature of homopolymeric stretches 
(Carracedo et al. 2000). Consequently, 249del is listed 
among the known control-region mutations in MITO- 
MAP. In the early literature, this deletion was often 
scored as 248del, as is testified, for example, by a Go­
ogle search using the entry “mtDNA 248d". Note that 
the current Uppsala mtDB database also employs the 
latter (outdated) convention, albeit not without prob­
lems: four haplogroup C sequences from Mishmar 
et al. (2003) bearing 249del are recorded - less parsi­
moniously - with 247del and A248G, which constitutes 
an artifact probably produced by some automatic 
alignment program.
Wong et al. (2002) considered the double deletion 
'286-291 del AA' as novel (see their Table 3); how­
ever, this deletion is diagnostic of haplogroup Cl and 
is, of course, well known: it is generally referred to as 
'290delA 291delA' (Carracedo et al. 2000) or '290- 
291del' or '290-291d'. A similar case is the variation in 
the short tandem CA repeat in region 514—523 (or 
alternatively interpreted as AC repeats in 515-524). In 
MITOMAP, the deletion or insertion of the dinucleo­
tide repeat can be found scored in at least ten different 
ways as 514C > CAC, 514delC, 515delA, 515delAC, 
516delC, 520C > CACACAC, 520delC, 520C > CAC, 
521delA, or 522delC, respectively. Despite this variety 
of possible scorings, an inadvertent base shift could 
then easily produce a seemingly novel mutation: in­
deed, Li et al. (2004) scored one deletion of the dinu­
cleotide repeat in this region wrongly as 515delCA and 
claimed, by referring to MITOMAP, that this was a 
previously unobserved mutational event.
Phantom mutations
Unusual ensembles of reported mutations may be due 
to artifacts generated in the course of the electropho­
resis (Bandelt et al. 2002: Brandstâtter et al. 2005). 
Quite often, such phantom mutations are predomi­
nantly transversions (Bandelt et al. 2005b: Bandelt and 
Kivisild 2006). For example, two-thirds of the muta­
tions provided by Abu-Amero et al. (2006) in their 
Tables 2 and 3 are transversions. It is then instructive 
to inspect these mutations more closely, which were 
detected in 26 medullary thyroid carcinomas but not 
found in “119 normal population controls and 284 
individuals with various mitochondrial disorders" 
according to the authors: novelty was decided by 
referring to the databases MITOMAP and mtDB. 
However, three (C4960T, A8836G, and C15247G) of 
the ‘novel' mutations were first published by Maca- 
Meyer et al. (2001), three (T11204C, C11665T, and 
T15672C) by Herrnstadt et al. (2002, 2003), two 
(T5093C and T15674C) by Achilli et al. (2004), and one 
(G5979A) by Tanaka et al. (2004). These mutations 
(with additional references) can all be retrieved from 
the mtDB database. The deletion of C at 16188 is not 
new either, as can be seen from a query to the SWG- 
DAM database. Additional Internet searches do not 
provide further hits, except for the 11708 mutation 
mentioned by Guan et al. (1998), which, however, 
constitutes an obvious typo. Thus, of the many muta­
tions listed in Tables 2 and 3 of Abu-Amero et al. 
(2006), only 26 have apparently not been observed 
before. The excess of transversions (23 transversions 
versus only three transitions) is now most dramatic. 
The fact that 20 of those transversions could only be 
captured by one amplified sequence fragment each (of 
a length exceeding 700 bp) makes it plausible that 
some phantom mutations could have slipped into the 
sequencing results because good readability of both 
strands might not have been guaranteed over the whole 
range.
It is most problematic when the potential pathogenic 
status of an observed mutation so strongly depends on 
the apparent novelty of the mutation, especially when 
the database search was incomplete. For example, the 
three mutations C4960T, C8472T, and A8836G de­
tected by Abu-Amero et al. (2006) belong to the 
ancestral mutation motif of haplogroup Nib according 
to Palanichamy et al. (2004). One should therefore be 
skeptical about the claim that A8836G affects protein 
function with “high confidence". Only a systematic 
analysis (including cybrid analysis) of a large number 
of mtDNA lineages from haplogroup Nib could sub­
stantiate such a claim.
New polymorphisms in retrospect
Jerónimo et al. (2001) reported the spectacular case of 
a patient seemingly bearing 18 somatic mutations in a 
tumor, which, with retrospective analysis, can be ex­
plained as a clear case of contamination or sample mix- 
up (Salas et al. 2005). In passing, Jerónimo et al. (2001) 
noted 23 “new polymorphisms" in 16 patients with 
prostate cancer, which were deemed to be novel 
germline mutations at the time. Among the 23 
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coding-region mutations listed, as many as 16 are now 
known to characterize certain haplogroups and another 
three occur as private mutations in the normal popu­
lation (as can be inferred from the mtDB database), so 
that only four mutations (A2335G, A12490G, 
A12777G, and C13623T) have hitherto not been ob­
served elsewhere (according to our search procedure). 
It is not clear whether the control region has been 
properly aligned to rCRS since the reported rCRS 
nucleotides at two positions (16094 and 16409) do not 
match the real rCRS nucleotides. Therefore, neither 
the spectrum of the “new" germline mutations nor the 
single somatic mutations in two tumors would indicate 
anything unusual that could support any particular role 
of mtDNA in prostate cancer.
The discovery of novel (homoplasmic) mtDNA 
variants in several mitochondrial dysfunctions is the 
leitmotif of the article by Crimi et al. (2002). However, 
more than 60% of the mutations reported by this group 
had already been reported elsewhere before their pa­
per was submitted (in May 2002); see Table 2. Most of 
these variants appeared in the 560 coding-region se­
quences of Herrnstadt et al. (2002), published in Jan­
uary 2002. One can then not quite agree with Crimi 
et al.'s claim that their "work can therefore help com­
plete the already ample mtDNA polymorphism existent 
database'', especially as the complete genomes - with 
all variants included - were not reported. This is par­
ticularly unfortunate in the case of the mtDNA of 
Patient 3, since this lineage belongs to the rare U2d 
haplogroup, for which only one (nearly) complete 
mtDNA sequence is available in the literature to date; 
see Palanichamy et al. (2004).
The article by Crimi et al. (2002) is in no way 
exceptional in this regard. We have investigated the 
published record for ‘novel' mutations from a further 
eight articles: see Table 2. For instance, Wong et al. 
(2002) performed a "comprehensive scanning of the 
entire mitochondrial genome for mutations" by ana­
lyzing 179 unrelated patients but did not report the 
observed haplotypes. Most (approx. 71%) of the 
“new" variants listed in that article are well-known 
polymorphisms in normal individuals (and approx. 
43% were known at the time of publication), many of 
which are diagnostic of particular branches of the 
mtDNA phylogeny.
The tale goes on
Tagging the term novelty to a mutation found (by 
chance) in some patient for whatever disease may be 
under study at that moment seems to enhance the 
chances for publication and is therefore applied to 
'spice up' a scientific contribution. A search of PubMed 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) for 
“novel" OR “new" AND “mtDNA" AND “muta­
tion" resulted in a list of 30 publications with these key 
words in the title and altogether 315 entries where 
these words appear in the title or abstract. In MITO­
MAP, a focused search for an (mtDNA) article bearing 
“novel" in its title even delivers 124 entries, most of 
which point to ‘novel' mtDNA mutations. For exam­
ple, Qu et al. (2006) included ‘novelty' of the mutation 
A4435G in the title of their paper - even though this 
mutation has been known about for a couple of years 
(Herrnstadt et al. 2002, 2003: Tanaka et al. 2004): 
Table 2 Efficiency of database search in the medical literature
Reference Type of study DBa nb Pc (%) Pd (%)
Fliss et al. (2000) Various tumors and body fluids [M]? 57 7 79
Jeronimo et al. (2001) Prostate cancer [M]? 27 22 78
Hibi et al. (2001) Esophageal cancer [M] 15 47 80
Jones et al. (2001) Pancreatic cancer cell lines [M] 49 12 71
Liu et al. (2001) Ovarian carcinoma [M]? 57 9 81
Crimi et al. (2002) Several disorders [M]? 33 61 70
Wong et al. (2002) Unrelated patients [M] 69 43 71
Chiu et al. (2003) Hydatidiform mole [M] 42 52 83
Linnartz et al. (2004) Myelodysplastic syndromes [M] 8 75 75
Abnet et al. (2004) Squamous cell carcinoma [M] 12 83 83
Da Pozzo et al. (2004) Encephaloneuromyopathy [M] 20 80 85
Abu-Amero et al. (2005) Thyroid carcinoma [M,U,G] 12 58 58
a DB, database search employed in the original study. [M], MITOMAP; [U], mtDB; [G] GenBank. A question mark indicates that the 
employed database is not explicitly indicated in the original reference but could be inferred from the context
b n, Number of claimed “novel" polymorphisms as reported in the original study
c Percentage of variants reported before the publication of the study 
d Percentage of variants hitherto reported in the literature
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querying the mtDB database reveals five occurrences 
in mtDNA sequences belonging to different haplo- 
groups (DI, D5a2, J2a, and M7a2). Similarly, the claim 
of Zhadanov et al. (2005) of having found a novel ND6 
mutation not previously reported (G14279A) is 
unjustified, since this mutation had already been found 
by Herrnstadt et al. (2002, 2003) in an mtDNA sample 
(no. 83). MITOMAP does not recognize this earlier 
appearance of G14279A and only cites Zhadanov et al. 
(2005).
As a matter of coincidence, both Zsurka et al. (2004) 
and Cardaioli et al. (2005) found the same ‘novel' 
heteroplasmic tRNAlcLllCl;X) mutation, G12276A, al­
beit in different disease contexts. This may well con­
stitute a pathogenic mutation, which, however, has not 
yet found its way into MITOMAP (as edited 25 Jan­
uary 2006), so it will probably be rediscovered again 
and again as a ‘novel' mutation in future studies. The 
advertisement "MITOMAP also maintains a compen­
dium of all known pathogenic mtDNA mutations" 
(Brandon et al. 2005) should certainly be taken with a 
pinch of salt.
The abstract of the paper by Ballana et al. (2006) 
announces the ‘novelty' of two mutations, T1243C and 
T1291C, in patients with hearing loss. The latter 
mutation has been found in a family of Cuban origin, 
but no haplogroup information is available from that 
study. Nonetheless we can conjecture that this mtDNA 
lineage belongs to a specific branch of the African 
haplogroup Llcl. Within this haplogroup, T1291C to­
gether with a further dozen mutations seem to define a 
sub-haplogroup, as can be inferred from two specific 
Llcl lineages - one from the USA (recorded by Her­
rnstadt et al. 2002, 2003) and one directly sampled in 
Africa (Kivisild et al. 2006). An independent occur­
rence of T1291C is reported within the South Asian 
haplogroup R6 (Palanichamy et al. 2004). Thus, 
T1291C is rather unlikely to be a disease-causing 
mutation despite the claim of Ballana et al. (2006). 
Given the fact that this mutation is essentially confined 
to a minor Llcl sub-haplogroup, it cannot come as a 
surprise that it would be absent in most control groups, 
especially if the control group is from Spain [see p 951 
of Ballana et al. (2006)], where the mtDNA input from 
sub-Saharan Africa is very low.
The first mention of the mutation T1243C in a dis­
ease context (aminoglycoside-induced deafness) was 
probably that of Bacino et al. (1995). This reference 
can be obtained via http://www.inchem.org/documents/ 
jecfa/jecmono/v51je02.htm, to which one is led to by a 
Google (or Google Scholar) search with query “human 
mtDNA T1243C". Since this first mention, the ‘nov­
elty' of this mutation has been a recurring, never­
ending theme (Schwartz et al. 1999; Jones et al. 2001; 
Taylor et al. 2001; Vives-Bauza et al. 2002; Zhu et al. 
2005; Ballana et al. 2006). The variant T1243C is, in 
fact, ubiquitous in West Eurasia: namely, the mtDB 
database harbors as many as 56 entries, 53 of which are 
from West and South Eurasia, all belonging to haplo­
group W; the three sporadic occurrences are from 
Africa (in haplogroups LOkl and LOdl). It remains to 
be asked why a mutational motif of a well-known ha­
plogroup is rediscovered over and over again by 
medical geneticists, who then declare one of its muta­
tions, T1243C, as novel. The answer lies in the two 
mouse clicks leading to MITOMAP: this mutation is 
recorded there only in connection with the pancreatic 
cancer cell lines of Jones et al. (2001) and has never 
been recognized as a (benign) polymorphism by MI­
TOMAP. The same fate is shared by the mutation 
C11674T that characterizes the super-haplogroup N2 
in which haplogroup W is nested (Palanichamy et al. 
2004): the latter is also listed as an “unpublished 
mtDNA polymorphism" connected with mental 
retardation (Mihailova 2006).
Conclusion
Internet searches involving only one to a few dozen 
clicks of the mouse will provide the searcher with a 
fairly complete picture of the published information on 
every single mtDNA mutation of interest, although for 
a few mutations the early (pre-Internet) literature 
would have to be consulted, especially in the case of 
control-region variants. All mtDNA lineages bearing 
the targeted mutation should then be located in the 
phylogenetic trees offered by any one (or more) web- 
site(s) or pertinent publication(s). This is the necessary 
homework that has to be done by the human geneticist 
before he/she can attempt to interpret the mtDNA 
mutation under investigation. Moreover, it is of crucial 
importance whether a mutation is highly recurrent and 
typically found as a private mutation or whether it 
constitutes an extremely rare event but defines only 
one or two minor basal haplogroups, as this would 
demand different strategies with respect to finding the 
appropriate control samples. There is no way to by­
pass or short-cut these steps. Many of the premature 
claims in a number of publications concerning the 
pathogenicity or disease-association of certain muta­
tions could have been avoided if, from the very outset, 
efficient search strategies and some degree of phylo­
genetic analysis had been performed (Bandelt et al. 
2005a, c; Salas et al. 2005). This also entails that com­
prehensive sequencing results should be published - 
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and not just a list of those mutations deemed to be 
‘novel' (Vega et al. 2004).
We provide here a first-aid algorithm for tracing 
mutations in the published record and subsequently 
hunting for their phylogenetic relevance. First, consult 
the cumulative databases MITOMAP and mtDB and 
look up the highlighted publications (if any). Then, 
enter the targeted mutation into several search engines 
by testing alternative designations, such as “T9137C", 
“9137T > C ", “9137C". or “9137", in connection with 
“human mtDNA" or “mitochondrial disease". In the 
next step the occurrences of the mutation in the 
mtDNA phylogeny have to be sorted out: a quick 
consult of Logan's website may assist the searcher in 
focusing subsequent searches. When the respective 
haplogroups. in which the targeted mutation thrives, 
and their (sub) continental mtDNA origin have been 
determined, one can then enter the key words “com­
plete mtDNA", “human mtDNA", “mtDNA phylog­
eny" (or “mtDNA tree"), and. for the geographic 
focus. “West Eurasian" (or “African", “East Asian", 
etc.). This would also help in obtaining an up-to-date 
view on the corresponding parts of the mtDNA phy­
logeny and the refined nomenclature.
The fact that a freshly detected mutation appears to 
be ‘novel' relative to the published record has abso­
lutely no significance within the framework of its po­
tential pathogenicity or disease-association - unless 
further compelling evidence is provided. For a homo­
plasmic mutation, the additional criteria “nonsynony- 
mous" and “evolutionarily conserved" are too soft to 
be of real relevance. A hitherto unobserved mutation 
could simply be part of the mutational motif of an 
infrequent haplogroup (Yao et al. 2006). On the other 
hand, a frequent mutation could very well be mildly 
deleterious, acting as a secondary disease-mutation in a 
complex multi-causal relationship together with other 
mtDNA mutations on a particular nuclear background. 
One should therefore recall the statement that “ii is 
difficult enough to identify frankly pathogenic mtDNA 
mutations, and it is obvious that proving haplogroup- 
associated polymorphisms act as risk factors will be 
commensurately more challenging" (Herrnstadt and 
Howell 2004).
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